Shield Therapeutics plc
STXStockLSE
6.50 ▲ +4.84%
Jun 12, 2026
S
Shield Therapeutics plc
6.50 ▲ +4.84%
Jun 12, 2026
STXStockLSE

About the company

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Arberion
Loading market data